| Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial SA Harrison, PJ Ruane, BL Freilich, G Neff, R Patil, CA Behling, C Hu, ... Nature medicine 27 (7), 1262-1271, 2021 | 238 | 2021 |
| A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis SA Harrison, PJ Ruane, B Freilich, G Neff, R Patil, C Behling, C Hu, ... JHEP Reports, 100563, 2022 | 45 | 2022 |
| Efruxifermin (EFX), a long-acting Fc-FGF21 fusion protein, administered for 16 weeks to patients with NASH substantially reduces liver fat and ALT, and improves liver histology … SA Harrison, PJ Ruane, BL Freilich, G Neff, R Patil, CA Behling, C Hu, ... Hepatology 72, 6A-7A, 2020 | 12 | 2020 |
| Efruxifermin (EFX) improved markers of fibrosis, liver injury and metabolism in F4 NASH patients with compensated cirrhosis S Harrison, P Ruane, B Freilich, G Neff, R Patil, C Behling, C Hu, ... Journal of Hepatology 75, S204-S205, 2021 | 5 | 2021 |
| Correlation between changes in liver fat content and improvements in serum markers of liver injury, fibrosis, and metabolism, and in histologic parameters following treatment … S Harrison, E TILLMAN, R SHRINGARPURE, C BEHLING, C HU, E FONG, ... Age (Years) 52 (50), 53, 2021 | | 2021 |
| The role of reduction in liver fat content (MRI-PDFF) and ALT in predicting treatment response in NASH: A secondary analysis of the randomized, controlled BALANCED trial R Loomba, E Tillman, C Hu, R Shringarpure, E Fong, B de Temple, ... Age (Years) 52, 54, 2021 | | 2021 |
| Efruxifermin Is Associated with Improved Glucose Metabolism in Patients with NASH and Type 2 Diabetes J Frias, R Shringarpure, E Tillman, C Hu, E Fong, B De Temple, T Rolph, ... Diabetes 70, 2021 | | 2021 |
